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Epilepsy represents the most common serious 
neurological problem affecting children, with an 
overall incidence approaching 2% for febrile 
seizures and 1% for idiopathic epilepsy1,2. Some 
authors define intractable epilepsy as failure of two 
appropriate AEDs, the occurrence of an average of 
one seizure per month for ≥ 18 months, and no 
more than a 3-month seizure free during those 18 
months3-5.  Recent findings in experimental models 
and in the clinical setting highlight the possibility 
that, inflammatory processes in the brain contribute 
to the etiopathogenesis of seizures and to the 
establishment of a chronic epileptic focus6-8. In 
many animal models of epilepsy acute seizures 
cause glial activation and increased cytokine 
production. The activated glia and elevated 
cytokines in turn  have been demonstrated to 
contribute to seizure-related hippocampal pathology 
such as neuronal death and reactive gliosis9.  
Platelet-activating factor (PAF) is a potent short-
lived phospholipid mediator of inflammation that 
participates in physiologic signaling in the brain.  It 
is a proinflammatory phospholipid that regulates 
the peripheral cytokines and inflammatory 
networks10. It is also involved in changes to 
vascular permeability, the oxidative burst, 
chemotaxis of leukocytes as well as augmentation 
of arachidonic acid metabolism in phagocytes. In 
the central nervous system sustained release of PAF 
is observed during ischemia, encephalitis, 
meningitis and epilepsy11. Another cytokine known 
as monocyte chemoattractant protein-1 (MCP-1) 
(also termed a monocyte chemotactic and activating 
factor (MCAF)12), belongs to the family of 
chemotactic cytokines known as chemokines, was 
found to be secreted by mononuclear cells and 
various non leukocytic cells including inflammatory 
fibroblasts and is synthesized by astrocytes and 
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Background: Epilepsy is an important common and diverse group of 
symptom complexes characterized by recurrent spontaneous seizures. It is 
estimated that about 5-10% of all cases of epilepsy eventually become 
refractory. It has been suggested that inflammation plays a role in epilepsy. 
In refractory epilepsy, an inflammatory response is produced that leads to 
rapid release of pro-inflammatory cytokines as platelet activating factor 
(PAF) and monocyte chemoattractant protein-1 (MCP-1).  
Objective: The aim of the present study was to evaluate the plasma levels of 
the monocyte chemoattractant protein-1 (MCP-1) and platelet activating 
factor (PAF) in children with refractory epilepsy to explore their role in the 
pathogenesis of refractory epilepsy.  
Methods: The present study was carried out in Tanta University Hospital, 
Pediatric Department, Neurology unit. Forty (40) children with idiopathic 
refractory epilepsy (25 males and 15 females) their age ranging between 4-
15 years were included in the study. The control group consisted of thirty 
healthy children, 20 males and 10 females aged 5 years to 13 years. The 
serum levels of MCP-1 and PAF were measured for children with refractory 
epilepsy and the control children. Results: Children with refractory epilepsy 
had significantly higher serum levels of PAF (P value<0.001) and 
significantly higher serum level of MCP-1 (P value<0.001) in comparison to 
the control children. Also there was a significant correlation between the 
duration of refractory epilepsy and the serum levels of PAF and MCP-1. 
Conclusion: Higher serum levels of the proinflammatory cytokines PAF and 
MCP-1 in children with refractory epilepsy suggest that both, PAF and 
MCP-1, may play a role in the pathogenesis of refractory epilepsy. 
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microglia within the brain parenchyma.  MCP-1 is 
consistently elevated in the brains in patients with 
refractory epilepsy13. MCP-1 aids in directing 
leukocytes to specific locales within the brain and 
spinal cord during central nervous system 
inflammation and directs the chemotaxis of 
monocytes and lymphocytes along concentration 
gradients in vitro. MCP-1 also mediates recruitment 
of macrophages/microglia and granulocytes during 
seizure injury14. 
This study aimed to investigate the serum levels the 
PAF and MCP-1 in children with refractory 




The present study was carried out in Tanta 
University Hospital, Pediatric Department, 
Neurology unit, during a 12-month period from 
January 2011 to January 2012. Forty (40) children 
with idiopathic refractory epilepsy 25 males and 15 
females, age range 4-15 years with the mean age of 
(9.17±3.4 years) were included in the study. 
Patients with refractory epilepsy had recurrent 
seizures for more than 18 months with no more than 
a 3-months seizure free during those 18 months and 
failure of at least two appropriate AEDs with proper 
doses, good compliance and within normal 
therapeutic range. Thorough history of the age of 
onset, detailed medical history  as regard the types 
of seizures  frequency, duration , history of the 
AEDs given including the dose and the compliance 
and duration  as well as family history of similar 
conditions, obstetric history of any complication 
during delivery and past history of  trauma were 
obtained from the parents. Electroencephalography 
(EEG), Magnetic Resonanace Imaging (MRI) brain, 
and the serum level of the AEDs were done for the 
epileptic children. Exclusion criteria including, 
false refractoriness related to nonepileptic seizures, 
inadequate AEDs, poor combination of AEDs, 
subtherapeutic range of AEDs, noncompliance, 
seizure-precipitating factors and children with any 
signs of central nervous system or any other 
infection. Also children with chronic inflammatory 
diseases, diabetes mellitus, liver or renal 
impairment, cardiac and pulmonary diseases were 
excluded from the study. Control group consisted of 
thirty (30) healthy children 20 males and 10 
females, with their age ranging between 5-13 years 
and their mean age 9.8±2.1 years. The control 
group had no history of any neurological or 
systemic diseases or any signs of systemic 
infections. The control children were matched with 
the patients as regards to sex and age. All children 
participated in the study after written informed 
parental consents had been obtained. The study had 
been approved by the local ethics committee of the 
Faculty of Medicine Tanta University. The serum 
levels of the PAF and MCP-1 were measured for 




Five ml venous blood samples were collected from 
each patient in the morning after an overnight 
fasting.  The fasting blood samples were allowed to 
clot for 30 minutes then centrifuged and the serum 
obtained were stored at -20°C into clean dry tubes 
until the time of determinations of the serum 
platelet activating factor (PAF) and monocyte 
chemoattractant protein-1 (MCP-1). 
 
Monocyte Chemoattractant Protein-1 (MCP-1) 
MCP-1 was measured by enzyme linked 
immunosorbant assay (ELISA) supplied with the kit 
(Ray Bio, Catalog n:ELH-MCP-1-0010). Standard 
and samples were pipetted into the wells and MCP-
1 present in the samples was bound to the wells by 
the immobilized antibody. The wells were washed 
and  a TMB substrate solution was added to the 
wells and color developed in proportion to the 
amount of leptin bound .The stop solution changed 
the color from blue to yellow, and the intensity of 
the color was measured at 450 nm. leptin bound. 
The stop solution changed the color from blue to 
yellow, and the intensity of the color was measured 
at 450 nm15. 
 
Quantitative determination of Human platelet 
activating factor (PAF) 
PAF was measured by immunoassay kit (ELISA) 
supplied by (EIAab Catalog No: E0526h). 
Standards and samples were added to the 
appropriate microtiter plate wells which had been 
pre-coated with an antibody specific to PAF. The 
biotin-conjugated polyclonal antibody preparation 
specific for PAF and Avidin conjugated to 
Horseradish Peroxidase (HRP) was added to each 
microplate well and incubated. Then a TMB 
substrate solution was added to each well. The 
enzyme-substrate reaction was terminated by the 
addition of a sulphuric acid solution and the color 
change was measured spectrophotometrically at a 
wavelength of 450 nm ± 2 nm16. 
 
Statistical analysis 
Collected data were coded, analyzed and computed 
using the Statistical Package for Social Sciences 
(SPSS) version 10. Results were expressed as mean 
PAF and MCP-1 in refractory epilepsy 
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±SD, and differences between the means of 
different variables were tested using the 
independent samples t-test. P <0.05 is considered 
significantly different. Pearson correlation was 
done to correlate the duration of refractory seizure 
and the serum levels of PAF and MCP-1.  
 
RESULTS 
Table (1) shows the characteristics of children with 
refractory epilepsy as regard the age of onset of the 
first seizure, the currently used AEDs and the EEG 
finding in each patient, the frequency of seizures 
and the duration of refectory seizures. The 
frequency of seizures was >/= Once /month in 70% 
of children with refractory epilepsy, >/= Once/week 
in 25% of children, once/day in 5% of children. The 
type of refractory seizures are classified as follow, 
partial seizures were found in 22 children with 
refractory epilepsy (55%), generalized tonic clonic 
seizures 6 children (15%), myoclonic seizures 4 
children (10%), atonic seizures 6 children (15%), 
mixed types of seizures 2 children (5%). The AEDs 
used in children with refractory epilepsy were,  
valproic acid +carbamazepine in 15% of children 
with refractory epilepsy , 30% of these children 
treated with valproic acids +levetiracetam, 20 % 
treated with lamotrigine +carbamazepine, 15% 
treated with valproic acid + Topiramate, 10% 
treated with Valproic acid +Levetiracetam 
+Carbamazepine, and 10 % treated with Valproic 
acid +Topiramate+ Clonazepam. Table (2) shows 
comparison between the mean serum PAF and 
MCP-1 in children with refractory epilepsy and the 
control children, the mean serum level of the PAF 
in children with refractory epilepsy was 107.4±11 
pg/ml this value was significantly higher than the 
mean serum level of the PAF in the control children 
which was 47.1±6 pg/ml (p<0.001). The mean 
serum level of the MCP-1 in children with 
refractory epilepsy was 90.4±6 pg/ml, this value 
was significantly higher than the mean serum level 
of the MCP-1 in the control children which was 
31.5±8 pg/ml (p<0.001). Figures (1,2) show 
significant correlation between the duration of 
refractory epilepsy and the serum levels of PAF and 
MCP-1 respectively. Increased duration of 
refractory epilepsy was associated with increased 





Table 1. Characteristics of children with refractory epilepsy. 
 
Age of the first seizure (years) 
Range  
Mean 










Generalized epileptogenic activity  
Focal epileptogenic activity 
Multifocal Generalized epileptogenic activity 
No abnormalities 
Number (percent) 
20  (50%) 
12  (30%) 
6    (15%) 
2    (5%) 
Frequency of seizures 
/= Once /month         
/= Once/week   
Once/day 
Number (percent) 
28  (70%) 
10  (25%) 
2    (5%) 
Currently used AEDs. 
Two  AEDs 
Three  AEDs 
Number (percent) 
32 (80%) 
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Table 2. Comparison between the mean serum PAF and MCP-1 in children with refractory epilepsy and the 
control children. 
 
P value Control  
children 































































r=0.968             p0.001 
 
Figure 1. Correlation between the mean serum levels of PAF and the duration of refractory epilepsy. 
 






































r=0.929             p0.001 
 
Figure 2. Correlation between the mean serum levels of MCP-1 and the duration of refractory epilepsy. 
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DISCUSSION 
It has been suggested that inflammation plays a role 
in epilepsy, inflammation is evoked by pro-
inflammatory modulators meant to protect from and 
heal injuries to the body17,18.  Pro-inflammatory and 
anti-inflammatory cytokines, chemokines and 
prostaglandins are responsible for the production of 
an early immune response19. Rodgers et al.20 
proposed that early inflammation largely increases 
neuronal excitability and after injury to the brain. 
An inflammatory response is produced by glial cells 
that lead to rapid release of pro-inflammatory 
cytokines.  It is suggested that rapid triggering of 
immune response in the brain can be a precursor to 
seizures21,22. The results of the present study had 
revealed that, children with refractory epilepsy had 
significantly higher serum levels of both PAF and 
MCP-1 than the control children (p<0.01).  After 
seizures PAF which is an endogenous 
proinflammatory agent that mediates neuronal 
survival and glutamate release was found to 
accumulate after seizures in the brain and activates 
intracellular signaling related to inflammation-
mediated excitotoxicity and hippocampal 
hyperexcitability23. Although PAF plays a role in 
the normal functioning of neurons, higher 
concentrations of PAF have been implicated in the 
neurotoxicity of epilepsy and contribute to neuronal 
damage in refractory epilepsy24. Increased seizure 
frequency is associated with increased neuronal and 
astrocytic injury and with massive glial activation 
and inflammatory responses in the epileptogenic 
cortex25. Microglial activation, astocytic 
proliferation and proinflammatory cytokine 
production may promote seizures, further 
exacerbate epilepsy and cause subsequent 
degeneration of neurons, astrocytes and 
oligodendrocytes26. The results of this study agree 
with pervious results done by Xu Yun et al.27, who 
found significantly elevated blood levels of PAF in 
children with epilepsy 72 hours following seizures 
in comparison to the control children.   On the other 
hand, MCP-1 is another proinflammatory 
chemokine that attracts cells involved in the 
immune/inflammatory response, it lays a significant 
role in the recruitment of monocytes and 
lymphocytes to the sites of cellular immune 
reactions28. A previous study done by Wu et al.29, to 
investigate the expression of MCP-1 in the brain 
tissue of patients with intractable epilepsy, had 
demonstrated that, expression of MCP-1 mRNA 
was upregulated in the brain tissue of patients with 
intractable epilepsy compared with that in the 
control group also expression of MCP-1 protein 
was significantly increased in patients with 
intractable epilepsy. Another experimental study 
done by Manley et al.30, in which they observed 
increased expression of MCP-1 in the rat 
hippocampus after induction of seizures. PAF and 
MCP-1 have been found to increase in the serum of 
children with refractory epilepsy with significant 
correlation to the duration of seizures. Thus, 
modulation of PAF and MCP-1 overactivity may 
attenuate seizure susceptibility, hippocampal 
hyperexcitability, and neuroinflammation, thus may 
be effective therapeutic strategies to prevent or limit 
epileptogenesis in children with refractory 
epilepsy31. 
In conclusion, the results of the present study 
suggest that plasma PAF and MCP-1 were elevated 
in children with refractory epilepsy. These results 
suggest that active neuroinflammation and marked 
cellular injury may play a common pathogenic role 
in children with refractory epilepsy. These results 
may suggest the need for a future novel therapeutic 
strategy to limit epileptogenesis and cell injury 
associated with refractory epilepsy.  
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